Sugi Predict

Sugi Predict / Compounds / SCHEMBL311327

SCHEMBL311327

SCHEMBL311327

O=[N+]([O-])c1cccc2[nH]cnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.50
▸ TXNRD1 Q16881 1/20 0.49
▸ TXNRD3 Q86VQ6 1/20 0.49
▸ TXNRD2 Q9NNW7 1/20 0.49
▸ NOS1 P29475 3/20 0.47
▸ PARP1 P09874 1/20 0.47
▸ PKN1 Q16512 1/20 0.47
▸ PKN2 Q16513 1/20 0.47
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ TDP1 Q9NUW8 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ NOS2 P35228 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6423203 1.00 PDE10A (0.50) PDE10ATXNRD1TXNRD3TXNRD2NOS1
Nitric Acid SCHEMBL8370806 0.95 PARP1 (0.47) PDE10ATXNRD1TXNRD3TXNRD2NOS1
Formic Acid SCHEMBL30908389 0.92 PARP1 (0.45) PDE10ATXNRD1TXNRD3TXNRD2NOS1
Ribose (Furanose) SCHEMBL5556119 0.80 SLC29A1 (0.40) PARP1ALDH1A1CYP1A2
SCHEMBL5675917 0.78 PARP1 (0.57) PDE10ATXNRD1TXNRD3TXNRD2NOS1
SCHEMBL5556182 0.77 SLC5A2 (0.37) PDE10APARP1PKN1PKN2MEN1
SCHEMBL4524595 0.76 ADORA3 (0.52) PDE10ATXNRD1TXNRD3TXNRD2NOS1
SCHEMBL6142551 0.76 MEN1 (0.53) PDE10AMEN1KMT2AALDH1A1TDP1
SCHEMBL20471929 0.76 TDP1 (0.46) PDE10AMEN1KMT2AALDH1A1TDP1
Nitric Acid SCHEMBL14695337 0.76 PARP1 (0.49) PARP1MEN1KMT2AALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1068 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630851-B2 Polynucleotide modification methods OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-05-19 — — US claimed
US-12624387-B2 Method for reducing primer dimer formation and increasing amplification efficiency SEEGENE, INC. (KR) 2026-05-12 — — US claimed
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 — — US claimed
US-12371736-B2 TD probe and its uses SEEGENE, INC. (KR) 2025-07-29 — — US claimed
WO-2024136630-A1 METHOD FOR SEQUENCE HOMOLOGY SEARCH OF NUCLEOTIDE DATABASE 주식회사 씨젠 2024-06-27 — — WO claimed
EP-4293127-A2 METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY Seegene, Inc. (KR) 2023-12-20 — — EP claimed
EP-4001428-B1 METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY SEEGENE INC (KR) 2023-11-22 — — EP claimed
EP-3286338-B1 AMPLIFICATION WITH PRIMERS OF LIMITED NUCLEOTIDE COMPOSITION Atila Biosystems Incorporated (US) 2023-11-01 — — EP claimed
CN-111362878-B Preparation method of 4-amino-1, 3-dihydro-benzimidazol-2-one 湖南复瑞生物医药技术有限责任公司 2023-09-19 — — CN claimed
CN-110168103-B Methods for reducing primer dimer formation and increasing amplification efficiency SEEGENE株式会社 2023-09-08 — — CN claimed
US-20050164184-A1 Hybridization portion control oligonucleotide and its uses SEEGENE, INC. (KR) 2005-07-28 — — US claimed
WO-2005045073-A1 METHOD FOR AMPLIFYING UNKNOWN DNA SEQUENCE ADJACENT TO KNOWN SEQUENCE SEEGENE, INC. (KR) 2005-05-19 — — WO claimed
CN-1602361-A Hybridization portion control oligonucleotide and use thereof SEEGENE INC (KR) 2005-03-30 — — CN claimed
CN-1578841-A Annealing control primer and use of the same VISION GENE CO LTD (KR) 2005-02-09 — — CN claimed
EP-1448795-A1 HYBRIDIZATION PORTION CONTROL OLIGONUCLEOTIDE AND ITS USES Seegene, Inc. (KR) 2004-08-25 — — EP claimed
EP-1448793-A1 ANNEALING CONTROL PRIMER AND ITS USES Seegene, Inc. (KR) 2004-08-25 — — EP claimed
US-20030175749-A1 Annealing control primer and its uses SEEGENE, INC. (KR) 2003-09-18 — — US claimed
US-20030119016-A1 Antisense oligonucleotides with increased RNase sensitivity THIRD WAVE TECHNOLOGIES, INC. 2003-06-26 — — US claimed
WO-2003050306-A1 HYBRIDIZATION PORTION CONTROL OLIGONUCLEOTIDE AND ITS USES SEEGENE, INC. (KR) 2003-06-19 — — WO claimed
WO-2003050305-A1 ANNEALING CONTROL PRIMER AND ITS USES SEEGENE, INC. (KR) 2003-06-19 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584168-B2 Sample preparation method POLN, POLRMT, POLM PDE10A 1284/4885TXNRD1 3056/4885TXNRD3 3966/4885
US-12630851-B2 Polynucleotide modification methods PNP, NT5C3B, UNG PDE10A 2323/4885TXNRD1 2720/4885TXNRD3 3004/4885
US-20030119016-A1 Antisense oligonucleotides with increased RNase sensitivity RNASE1, RNASEL, RNASEH1 PDE10A 4263/4885TXNRD1 1030/4885TXNRD3 627/4885
US-12624387-B2 Method for reducing primer dimer formation and increasing amplification efficiency UBR4, UBAP2, UBAP2L PDE10A 4681/4885TXNRD1 1772/4885TXNRD3 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.